Petra Larson

Management assistant and communications lead

Role in PharmNovo: Management assistant and communications lead.

Born: 1969.

Education: Postgraduate diploma in Strategic marketing (DipM Chartered institute of marketing), University certificate in polymer technology, Project management, pharmacology and digital marketing.

Other current appointments: None.

Work experience: Petra has over 20 years of experience from the pharma industry within product development, digital communications and marketing. She has worked for AstraZeneca and other pharma companies as well as for digital agencies during these years. When working for AstraZeneca as Global e-business manager she gained extensive experience in digital marketing and project management. During a few years she also held a position as project manager in an digital agency.

Holdings: None.

Member of:

Operational team

Latest news

View all

March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

Meet Bengt von Mentzer, founder and Chief scientific advisor

March 10, 2024

Meet Bengt von Mentzer, founder and Chief scientific advisor

Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.

January 30, 2024

NIDA funds studies

The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.

Meet Olof Breuer, MD, Clinical pharmacology lead

January 30, 2024

Meet Olof Breuer, MD, Clinical pharmacology lead

Olof Breuer's presence at PharmNovo exemplifies the company's commitment to pioneering advancements in pain relief. His visionary approach, honed through years of experience, positions him as a driving force in the quest for novel concepts in neuropathic pain relief.